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Background: Physicians frequently differ in their treatment recommendations. However, few studies have
examined the reasons underlying these differences. The objective of this study was to examine whether physicians
vary in the importance they attach to specific adverse events for two treatment options found in recent
randomized controlled trials to have equivalent efficacy and overall toxicity.
Methods: A Max-Diff survey was administered to physicians attending a national scientific conference to quantify
the influence of 23 specific adverse events on decision making related to two treatment options for vasculitis.
This approach was chosen because it results in greater item discrimination compared to rating scales. We used
Hierarchical Bayes modeling to generate the relative importance score for each adverse event and examined the
association between physicians’ characteristics and the five most influential factors.
Results: 118 physicians completed the survey. The mean age (SD) was 48 years (10); 68% were male and 81%
reported spending the majority of time in clinical practice. There was significant variability in the ratings of the
relative importance of all adverse events, except those that were mild and easily reversible. We found a positive
correlation between increasing physician age with ratings of sepsis (r = 0.29, p = 0.002) and opportunistic infection
(r = 0.23, p = 0.016), and an inverse association between age with progressive multifocal leukoencephalopathy
(r = − 0.28, p = 0.003). Physician sex, work setting, location, and number of patients with vasculitis seen per year
were not associated with the influence of specific adverse events on decision making.
Conclusion: Our findings demonstrate that physicians differ substantially in how they perceive the importance of
specific adverse events which may help explain observed unwarranted variability in physicians’ recommendations in
clinical practice. Further efforts are needed to ensure that the reasons underlying variability in physicians’
recommendations are transparent.
Keywords: Vasculitis, Decision-making, Drug toxicity, Cyclophosphamide, Rituximab, Best-worst scalingBackground
Physicians often differ in their treatment recommenda-
tions. Extant reports of patients receiving significantly
different recommendations by physicians practicing in
different locations have been published both in the med-
ical literature and the lay press. This variability persists
even among experts who are well versed in the same
literature as illustrated by the publication of conflict-
ing guidelines by separate organizations [1]. However,* Correspondence: Liana.Fraenkel@yale.edu
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unless otherwise stated.few studies have systematically examined the reasons
underlying these differences. Variability in recommenda-
tions likely occurs more often under conditions of uncer-
tainty where there are few high quality studies available to
inform decisions [2]. In these situations, indirect evidence
is frequently relied upon to inform decision making in
clinical practice. This is especially true for less common
conditions, such as vasculitis.
Anti-neutrophil cytoplasmic antibodies (ANCA)-
associated vasculitis (AAV) refers to a group of life- and
organ-threatening diseases characterized by inflammation
of small blood vessels, most commonly involving the skin,
lungs, and kidneys. When vasculitis was first described,
glucocorticoids were the only available treatment. Theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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in significant improvements in overall survival of patients
with vasculitis. However, cyclophosphamide is associated
with significant toxicity including infection, infertility, and
cancer, and physicians have long sought safer alternatives.
In 2010, two randomized controlled trials, Rituximab
in ANCA-Associated Vasculitis (RAVE) and Rituximab
versus Cyclophosphamide in ANCA-Associated Vascu-
litis (RITUXVAS) [3,4], demonstrated that rituximab is
as effective as cyclophosphamide at inducing remission
in patients with moderate to severe disease. Moreover,
there were no differences in the rate of adverse events
between the two groups. These results provided physi-
cians with an alternative treatment option for AAV for
the first time in approximately 40 years.
Given the equivalent rates of remission and toxicity in-
duced by both treatment regimens, the decision of which
treatment to initiate (assuming the patient has no con-
traindications to either option) is likely strongly influenced
by judgments related to the impact of specific adverse
events. The RAVE trial was designed as a non-inferiority
trial because physicians believed rituximab to be a po-
tentially safer alternative. This belief was based on a large
body of indirect evidence generated from randomized tri-
als and observational studies of patients with different dis-
eases or using different treatment regimens demonstrating
a lower risk of infection associated with rituximab com-
pared to cyclophosphamide [5-26]. Moreover, unlike cy-
clophosphamide, rituximab is not associated with a risk of
infertility or cancer. However, the RAVE and RITUXVAS
trials, which are the only head-to-head comparisons of cy-
clophosphamide and rituximab in any disease, demons-
trated no significant differences in toxicity between the
two treatment arms, including serious infection or rates of
hospitalization. Several of the major toxicities of concern
for cyclophosphamide, including ovarian failure and blad-
der cancer, usually manifest after either higher cumulative
doses of cyclophosphamide or longer follow-up times
than present in the trials under discussion. Despite theseFigure 1 Example of choice task.limitations, the RAVE and RITUXVAS trials led not only
to the approval of rituximab for use in AAV by the US
Food and Drug Administration and regulatory agencies in
other countries, but also rapid widespread adoption of the
drug’s use as an remission induction agent in AAV.
The objective of this study was to quantify the influ-
ence of specific adverse events on physicians’ treatment
decisions for patients with newly-diagnosed AAV. Rela-
tive importance of specific attributes are most commonly
measured using rating or ranking tasks. Visual analogue,
Likert, or numeric rating scales are relatively easy to per-
form and permit inclusion of a large number of items.
However, such rating scales are influenced by response
biases, including social desirability bias and extreme re-
sponse bias [27]. The latter is particularly problematic
in healthcare research where subjects tend to rate all
items as “Extremely Important”. Ranking tasks provide
better discrimination, but significantly limit the number
of items that can be included in a survey. In this study
we used Sawtooth Software’s MaxDiff program as an al-
ternative to a rating or ranking task. This approach asks
respondents to choose the best (or the most important)
item and/or the worst (or least important) item from a
series of sets containing different combinations of items
from a master list (see Figure 1 for an example). This
method has several important advantages over rating
scales including the ability to handle a large number of
attributes, greater item discrimination, and avoidance of
scale-related response bias [28].Methods
We administered a MaxDiff survey to a convenience sam-
ple of physicians attending the 2010 American College
of Rheumatology National Scientific Meeting [29]. The
survey was designed using Sawtooth Software (Sawtooth
Software SSI Web version 6.4) and included 23 adverse
events associated with either RTX and/or cyclophospha-
mide. Participants were given the following instructions:
Table 1 Relative importance scores for each adverse event
Adverse events Mean Median SD Range
Sepsis 11.3 11.3 1.6 5.4-14.7
Serious infection 11.0 11.3 2.1 4.0-14.8
Bone marrow suppression 8.0 8.5 2.9 0.3-13.8
Opportunistic infection 7.7 8.0 3.0 0.4-13.9
Lymphoma 6.9 7.2 3.1 0.1-11.3
Malignancy 6.7 7.7 3.5 0.1-13.1
Bladder cancer 6.6 7.0 2.8 0.1-11.5
Serious infusion reaction 5.8 5.7 3.8 0.1-13.7
Progressive multifocal
leukoencephalopathy
5.3 4.6 3.7 0.03-13.4
Myelodysplasia 4.9 4.6 2.5 0.5-10.2
Hemorrhagic cystitis 4.6 4.3 2.6 0.2-12.2
Hepatitis 4.2 3.5 2.9 0.1-11.6
Myocardial damage 3.4 3.1 2.6 0.1-11.1
Interstitial lung disease 3.4 2.8 2.6 0.1-10.8
Leukopenia 3.4 1.8 3.5 0.03-13.9
Serious skin reaction 3.3 2.4 2.4 0.2-11.4
Zoster 1.8 1.2 1.7 0.05-10.0
Mild infection 0.5 0.1 1.1 0.004-6.7
Mucositis 0.4 0.1 0.8 0.002-6.7
Alopecia 0.2 0.03 0.4 0.0009-3.1
Nausea 0.1 0.03 0.8 0.002-8.4
Mild infusion reaction 0.06 0.02 0.1 0.001-0.5
Mild skin reaction 0.05 0.009 0.2 0.0008-1.5
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(given your knowledge about the severity and
probability of each of the adverse events) how much
each adverse event influences your decision about
which medication to prescribe for a 50 year old
post-menopausal woman with newly diagnosed severe
ANCA-associated vasculitis. Assume the patient is
hospitalized with pulmonary and renal involvement”.
We described the patient as being a postmenopausal
woman so as to eliminate fertility concerns, which are ex-
tremely variable and difficult to control for in a standard-
ized scenario. The survey asked respondents to choose the
most important item from 20 sets containing different
combinations of five items from the master list of 23 ad-
verse events (see example in Figure 1).
The survey design ensured that each item 1) was shown
approximately an equal number of times, 2) was paired
with each other item an equal number of times, and 3) ap-
peared in each position an equal number of times. We
also collected data on the following physician characteris-
tics: age, sex, number of years of experience, work setting,
and the number of patients with vasculitis seen per year.
We used Hierarchical Bayes modeling to generate the
mean relative importance score for each adverse event.
The relative importance scores sum to 100, and reflect
the impact of each characteristic on physicians’ decision
making. For each respondent, utilities (zero-centered
values) were calculated for each level of each attribute
using Hierarchical Bayes (HB) modeling (Sawtooth CBC/
HB system for hierarchical Bayes estimation version 4.0).
HB modeling has the advantage that it can better in-
corporate heterogeneity between respondents’ choices. In
HB modeling, the sample averages (prior information) are
used to update the individual utilities in a number of itera-
tions until the sample averages stop changing between it-
erations. After this convergence, the cycle is run several
thousand more times and the estimates of each iteration
are saved and averaged. Raw scores were rescaled to
a 0 to 100 on a ratio scale [30]. The associations be-
tween physician characteristics and ratings were made
using Pearson’s correlation coefficient and chi-square
tests for continuous and categorical variables, respectively.
This study qualified for exemption as determined by the
Yale Human Investigation Committee.
Results
One hundred and eighteen physicians completed the sur-
vey: 75 from North America and 22 from Europe. The
mean age (SD) was 48 (10) years; 68% were male; 81% re-
ported spending the majority of time in clinical practice;
39% work in an academic setting; 7% see fewer than 1 pa-
tient with AAV per year, 46% between 1 and 5 patients
with AAV per year; 22% between 6 and 10 patients withAAV per year, and 25% see more than 10 patients with
AAV per year.
Physicians’ relative importance scores for each adverse
event are provided in Table 1. Overall, physicians’ deci-
sions were most strongly influenced by the risk of infec-
tion and cancer. As noted by the ranges in Table 1 and
the histograms illustrating the distributions of the mean
relative importance of each adverse event (Figure 2),
there was significant variability in the ratings of all ad-
verse events, except those that were felt to be the least
important. Figure 3 provides a full sized example of a
mild and serious adverse event.
We examined the association between physicians’ char-
acteristics and the five of the most influential factors:
sepsis, lymphoma, opportunistic infection, serious infu-
sion reaction, and progressive multifocal leukoencepha-
lopathy. There was a positive correlation with increasing
physician age with ratings of sepsis (r = 0.29, p = 0.002)
and opportunistic infection (r = 0.23, p = 0.016). In con-
trast, older rheumatologists’ decisions were less influenced
by progressive multifocal leukoencephalopathy (r = − 0.28,
p = 0.003). The association between age and lymphoma
was of borderline significance (r = − 0.19, p = 0.05) and
Figure 2 Snapshot of histograms representing variability in relative importance assigned to each adverse event.
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fusion reaction (r = 0.02, p = 0.9).
Ratings of all adverse events by age group (up to 39,
40-55, 56+ years of age) are illustrated in Figure 4. Com-
pared to younger physicians, older physicians were more
strongly influenced by the risk of serious infection-
related adverse events (except for progressive multifocal
leukoencephalopathy) and less strongly influenced by
malignancy. Physician sex, work setting, location, and
number of patients with vasculitis seen per year were
not associated with the impact of sepsis, lymphoma,Figure 3 Relative importance assigned to a Mild AE (Alopecia) and aopportunistic infection, serious infusion reaction, and
progressive multifocal leukoencephalopathy on deci-
sion making.
Discussion
The findings from this study demonstrate that physicians
differ significantly in the impact that specific adverse
events have on their decision making. With the exception
of reversible and easily treatable adverse events, histo-
grams showed wide distributions for all adverse events
related to the two treatment options examined. Ratingsserious AE (Malignancy).
Figure 4 Mean relative importance scores by age group.
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find differences by age group, with physicians greater than
56 years old being more influenced by the risks of all
infection-related adverse events, except for progressive
multifocal leukoencephalopathy, than their younger coun-
terparts. While the data do not explain the reasons under-
lying this pattern, it is possible that the differential impact
between unspecified serious infections and progressive
multifocal leukoencephalopathy is due to the relative re-
cent attention focusing on the latter [31-33].
The RAVE [3] and RITUXVAS [4] head-to-head ran-
domized controlled trials demonstrated no significant
differences in the risk of infection between the two re-
gimens. Despite these results, physicians ranked the risk
of infection as the most important factor influencing
their treatment decision. This finding was especially pro-
nounced among older physicians. Physicians may under-
value risk estimates generated from randomized trials,
because selective eligibility criteria, strict protocols, and
short-term follow-up minimize adverse events. In addi-
tion, many of the risks associated with immunosuppres-
sive medications are rare and would not be expected to
occur in trials with relatively small numbers of patients.
Small numbers and short duration of follow-up limit the
usefulness of the toxicity data generated from head-to-
head randomized controlled trials, however, the use of in-
direct data also has significant limitations. Most notably,
the indirect data available for cyclophosphamide were ge-
nerated from trials using higher doses of the drug and formuch longer periods of time compared to the regimens
currently used. This is particularly important because the
most worrisome adverse events associated with cyclophos-
phamide (i.e. infection, infertility, and malignancy) are
dose dependent.
There are several important limitations of this study.
The use of standardized scenarios, enabled us to syste-
matically vary patient characteristics, but this approach
cannot replicate the complexity of decision making in
clinical practice. In addition, although we surveyed a large
number of physicians, most of whom spend the majority
of their time in clinical practice, the study population rep-
resents a convenience sample of consecutively approached
volunteers, which limits generalizability. Future research
should examine whether differences in decision making
predict differences in treatment choices made in clinical
practice.
Conclusions
Ideally, despite physicians differing in their judgments,
patients should all receive the same information describ-
ing potential treatment options and the reasons under-
lying variability in physicians’ recommendation should
be transparent. While we did not measure actual treat-
ment decisions, these findings suggest that physicians
differ substantially in how they perceive the importance
of specific adverse events which may help explain the fre-
quently observed unwarranted variability in physicians’
recommendations.
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